Document is current
Any future updates will be listed below
-
Authors
Bartholomew, Alex J.
Rhodin, Kristen E.
Noteware, Laura
Moris, Dimitrios
Kanu, Elishama
Masoud, Sabran
Howell, T. Clark
Burner, Danielle
Kim, Charles Y.
Nussbaum, Daniel P.
Zani, Sabino
Lidsky, Michael E.
Allen, Peter J.
Riedel, Richard F.
Blazer, Dan G. III
- License Information
-
More Information
Article History
Received: 13 May 2024
Accepted: 16 July 2024
First Online: 12 August 2024
Disclosures
: Richard Riedel has received institutional clinical research support from AADi, Adaptimmune, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, Tracon, and Trillium; and is a consultant/advisor for AADi, Adaptimmune, Bayer, Blueprint, Boehringer Ingelheim, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, NanoCarrier, and SpringWorks. Alex J. Bartholomew, Kristen E. Rhodin, Laura Noteware, Dimitrios Moris, Elishama Kanu, Sabran Masoud, T. Clark Howell, Danielle Burner, Charles Y. Kim, Daniel P. Nussbaum, Sabino Zani, Michael E. Lidsky, Peter J. Allen, and Dan G. Blazer have no conflicts of interest to declare that may be relevant to the contents of this article.
